News

Gut Microbiota Metabolite Linked to Growth and Spread of Rectal Cancer

Research Advances /

A study found that changes in gut bacteria and their metabolites may play an important role in rectal adenocarcinoma (READ). Researchers compared stool samples from 33 patients with rectal cancer and 34 healthy individuals and identified major differences in gut microbiota and metabolic activity. One key finding was that guanidinoacetic acid (GAA), a metabolite involved […]

Gut Microbiota Metabolite Linked to Growth and Spread of Rectal Cancer Read More »

Lightweight AI Model Achieves High Accuracy in Lung Cancer Detection from CT Scans

Technology Innovation /

A study presents a new lightweight deep learning model that can classify lung cancer from CT scans with very high accuracy while using far less computing power than traditional methods. Researchers combined EfficientNetB0 with a lightweight attention system and a capsule-style feature module to better detect and analyze lung nodules. Unlike older capsule networks, the

Lightweight AI Model Achieves High Accuracy in Lung Cancer Detection from CT Scans Read More »

New Advances Reshape Treatment Approach for Polycythemia Vera

Treatment /

Treatment of polycythemia vera (PV) is shifting from focusing only on hematocrit control to a broader approach that also targets white blood cells, platelets, and symptoms. Data from large studies like REVEAL study show that higher levels of white blood cells and neutrophils, not just hematocrit, are linked to increased risk of blood clots. Keeping

New Advances Reshape Treatment Approach for Polycythemia Vera Read More »

EU Approves Tovorafenib for Pediatric Low-Grade Glioma with BRAF Alterations

Drug Approvals /

The European Commission has granted conditional approval to tovorafenib (Ojemda) for children aged 6 months and older with relapsed or refractory pediatric low-grade glioma (pLGG) carrying BRAF alterations. This is the first systemic therapy specifically approved in the EU for BRAF-rearranged pLGG. The decision is based on results from the FIREFLY-1 trial, where the drug

EU Approves Tovorafenib for Pediatric Low-Grade Glioma with BRAF Alterations Read More »

Tumor Structure Predicts Immunotherapy Success in Melanoma, Study Finds

Immunotherapy /

A study found that the physical arrangement of immune cells inside melanoma tumors plays a key role in determining whether immunotherapy works. Researchers analyzed tumor samples from patients in the SWOG S1616 clinical trial using advanced imaging and genetic tools. They discovered that patients who responded to treatment had active CD8 T cells clustered close

Tumor Structure Predicts Immunotherapy Success in Melanoma, Study Finds Read More »

Sac-TMT Shows Promising Activity in Advanced Urothelial Cancer After Prior Treatments

Treatment /

After Prior Treatments A phase 1/2 study (2870-001/KL264-01) reports that sacituzumab tirumotecan (sac-TMT), a TROP2-targeting antibody-drug conjugate, shows strong antitumor activity in patients with advanced or metastatic urothelial carcinoma who have already failed standard treatments. Among 49 heavily pretreated patients, the overall response rate was 31%, with higher responses (50%) in those who had only one

Sac-TMT Shows Promising Activity in Advanced Urothelial Cancer After Prior Treatments Read More »

More Daily Steps Can Offset Health Risks of Prolonged Sitting, Study Finds

Research Advances /

A study shows that increasing daily steps can reduce the health risks of prolonged sitting. Using data from more than 72,000 participants in the UK Biobank, researchers tracked activity and health outcomes over nearly seven years. They found the greatest benefits at 9,000–10,000 steps per day, lowering the risk of death by 39% and cardiovascular

More Daily Steps Can Offset Health Risks of Prolonged Sitting, Study Finds Read More »

mRNA-4359 Boosts Keytruda Response, Showing High Success Rates in Advanced Melanoma

Immunotherapy /

Results from a Phase 1/2 study show that mRNA-4359, an experimental cancer vaccine, can greatly improve the effectiveness of pembrolizumab (Keytruda) in treating advanced melanoma. In a small group of patients, the combination achieved an 83% response rate and a 92% disease control rate. Patients responded quickly, with tumor shrinkage seen in about six weeks,

mRNA-4359 Boosts Keytruda Response, Showing High Success Rates in Advanced Melanoma Read More »

Novel “Molecular Glue” Drug NST-628 Shows Strong Results in Hard-to-Treat Melanoma and Brain Tumors

Targeted Therapy /

Data shows that NST-628, a new “molecular glue” drug targeting the RAF/MEK pathway, may offer a promising treatment for patients with NRAS and BRAF class II/III mutant melanoma, who currently have few targeted therapy options. In an early phase clinical trial involving heavily pretreated patients, NST-628 showed strong anti-cancer activity. In melanoma patients, it achieved

Novel “Molecular Glue” Drug NST-628 Shows Strong Results in Hard-to-Treat Melanoma and Brain Tumors Read More »

ctDNA-Guided Strategy Shows Promise for Early Detection and Prevention of Head and Neck Cancer Recurrence

Precision Medicine /

Results from the phase 2 MERIDIAN trial show that circulating tumor DNA (ctDNA) can help detect and guide treatment of residual disease in patients with locally advanced head and neck squamous cell carcinoma. Researchers used the RaDaR assay, a personalized blood test, to monitor patients after treatment. The test showed very high accuracy, with positive

ctDNA-Guided Strategy Shows Promise for Early Detection and Prevention of Head and Neck Cancer Recurrence Read More »